More information about Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukemia.

[Jm954]

Aug 2019

This complex, technical but fascinating paper discusses the standardized and new innovative technical approaches for MRD detection in CLL, the clinical impact of MRD monitoring in trials and the future clinical implications of MRD monitoring in CLL patients outside of clinical trials.

Importantly, MRD analysis has been recently approved as an intermediate/surrogate endpoint to assess treatment efficacy in randomized clinical trials designed to show a superiority in terms of PFS in CLL patients by the European Medicines Agency (EMA) with patients who achieve clinical CR and uMRD (<10−4) being considered MRD responders. However, the predicted benefit on PFS needs to be confirmed with longer follow-up.

If you're interested in MRD monitoring then this paper is worth a read, masses of information here. frontiersin.org/articles/10...

Jackie

[Ernest2]

What a great paper. I'm going to get into trouble for reading it all.

Lots of other useful stuff as well as MRD.

Many thanks,

Ernest

[ChrisLovesLife]

Fascinating read, as always, thank you for your diligence Jackie!